Melanosis
Drug research and approvals for melanosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 15 studies of melanosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 15
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Chinese Multicenter Registry for Peutz-Jeghers SyndromeNCT07889596 · Not reported · First People's Hospital of Hangzhou · starts Nov 1, 2026
- Efficacy Evaluation of a Cosmetic Product for Facial HyperpigmentationNCT07769268 · Not applicable · Brainfarma Industria Química e Farmacêutica S/A · starts Jul 13, 2026
- A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult…NCT07679945 · Not applicable · Kenvue Brands LLC · starts Jun 2, 2026
- Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for MelasmaNCT07540702 · Not applicable · Kasr El Aini Hospital · starts Feb 1, 2026
- Ultrasound-Enhanced Delivery of Compound TXA Solution in MelasmaNCT07202156 · Not applicable · The First Affiliated Hospital with Nanjing Medical University · starts Oct 20, 2024
- COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYSNCT07071363 · Not applicable · Laboratoire Dermatologique ACM · starts Jun 23, 2025
- Oral Metformin for Treating Melasma in Latin American WomenNCT06845540 · Phase 1 / Phase 2 · University of Puerto Rico · starts Feb 20, 2025
- Celecoxib for Prevention of Progression in Peutz-Jeghers SyndromeNCT06722534 · Not applicable · Air Force Military Medical University, China · starts Feb 1, 2025
- Randomized Study Using SM-030 Gel for Adults With MelasmaNCT06454747 · Phase 2 · DermBiont, Inc. · starts Jun 27, 2024
Approved 8
- Hydroquinone
- TretinoinRetinoic acid receptor agonist
- Fluocinolone acetonideGlucocorticoid receptor agonist
- OctocryleneSunscreen
- Avobenzone
- OxybenzoneSunscreen
- Octinoxate
- Padimate o
Phase 3 1
- Tranexamic acidPlasminogen inhibitor
Phase 2 5
- Niacinamide
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- TriamcinoloneGlucocorticoid receptor agonist
- ArbutinTyrosinase inhibitor
- Silybin a
Phase 1 or earlier 6
- Glycolic acid
- IsotretinoinRetinoic acid receptor agonist
- SpironolactoneMineralocorticoid receptor antagonist
- Azelaic acid
- Platelets
- Salicylic acid
How its trials ended
118 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 21% met their primary endpoint, 0% missed it and 79% stopped early.
- Completed, result not reported5547%
- Ongoing2622%
- Status unknown2319%
- Stopped: other or unclear87%
- Met its primary endpoint33%
- Stopped: enrollment or feasibility33%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA